Sermorelin vs Tesamorelin vs CJC-1295: Three GHRH Analogs Compared

For research & educational purposes only. This article is a neutral, procedural reference for laboratory / in-vitro research handling — not medical advice or a usage recommendation. These materials are not for human or animal consumption.

The short answer

All three are GHRH analogs acting at the same receptor. Sermorelin is the shortest - a 29-amino-acid fragment corresponding to the biologically active region of natural GHRH. Tesamorelin is a stabilised analog with the most extensive published human trial record of the three. CJC-1295 is modified for an extended duration of action. The receptor is shared; the stability and the evidence are not.

	Sermorelin	Tesamorelin	CJC-1295
Receptor	GHRH receptor	GHRH receptor	GHRH receptor
Structure	GHRH(1-29) fragment	Stabilised GHRH analog	Modified long-acting analog
Duration profile	Short	Short to moderate	Extended
Published human data	Moderate, older literature	Most extensive of the three	Limited
Why studied	Closest to native GHRH	Stability and trial depth	Duration

Same receptor, different modifications and very different evidence depth.

Sermorelin: the native fragment

Natural GHRH is a 44-amino-acid peptide, and research established that the first 29 residues carry the receptor activity. Sermorelin corresponds to that fragment. Its research interest comes from being the closest of the three to the native signalling molecule, which makes it useful where a study wants minimal deviation from endogenous structure. The trade is stability - the unmodified fragment is shorter-lived than the analogs designed after it.

Tesamorelin: stabilised, and the best documented

Tesamorelin is a GHRH analog modified for improved stability. Of the three it carries the most extensive published human trial record, which for a researcher is the most consequential difference on this page - it means comparisons against published endpoints are possible in a way they are not for the other two.

CJC-1295: built for duration

CJC-1295 was modified specifically to extend how long the molecule persists. That makes it the distinct case where duration rather than fidelity to the native sequence is the property under study. Its published human data is more limited than tesamorelin's, and research designs should account for that rather than transferring conclusions across the family.

What they are not

None of the three is interchangeable with a growth-hormone secretagogue such as ipamorelin, which acts at the ghrelin receptor rather than the GHRH receptor. Compounds acting on the same axis through different receptors are compared separately - see the GHRH versus secretagogue comparison for that distinction.

Compounds referenced here are supplied as analytical-grade reference materials for in-vitro and laboratory research only. Nothing on this page is a recommendation for human or veterinary use.

Frequently asked questions

What is the difference between sermorelin and tesamorelin?

Both act at the GHRH receptor. Sermorelin is the GHRH(1-29) fragment, the shortest form retaining receptor activity, while tesamorelin is a stabilised analog with a longer duration and a considerably larger published human trial record.

Is CJC-1295 stronger than sermorelin?

CJC-1295 was modified for extended duration rather than for greater potency at the receptor, so the difference is how long it persists rather than how hard it acts. The two also differ substantially in published evidence depth, and neither difference is well described as one being stronger.

Which GHRH analog has the most published research?

Tesamorelin has the most extensive published human trial record of the three. Sermorelin has a moderate and largely older literature, and CJC-1295's published human data is the most limited.

Are GHRH analogs the same as secretagogues like ipamorelin?

No. GHRH analogs such as sermorelin, tesamorelin and CJC-1295 act at the GHRH receptor. Ipamorelin acts at the ghrelin receptor, GHS-R. Both engage the growth-hormone axis but through different receptors, which is why they are studied together rather than as substitutes.

Published research

A selection of peer-reviewed and clinical literature indexed on PubMed. Provided so qualified researchers can locate the primary sources — inclusion here is not a claim about any product or outcome.

VNG Research Team

VNG Labs supplies analytical-grade reference materials with lot-matched Certificates of Analysis. Our write-ups are neutral, source-cited references for qualified and independent researchers.